Skip to main content
Premium Trial:

Request an Annual Quote

Provista Signs Licensing Agreement for ASU Biomarker Technologies

NEW YORK (GenomeWeb News) – Provista Diagnostics said today that it has licensed biomarker technologies developed by researchers at Arizona State University's Biodesign Institute.

The company will evaluate the technologies for use in the early detection of breast cancer, ovarian cancer, and human papillomavirus.

The licensed technologies were developed primarily in the labs of Biodesign Institute researchers Joshua LaBaer and Karen Anderson, both of whom work extensively with protein microarrays. LaBaer and Anderson are both members of Provista's scientific advisory board.

"With the advent of molecularly-targeted therapeutics, biomarkers that are associated with biological subtypes of cancer may be useful for predicting responses to therapeutic interventions," LaBaer, director of the Virginia G. Piper Center for Personalized Diagnostics at the Biodesign Institute at ASU, said in a statement. "If we can significantly advance the early detection of these cancers, we can save thousands of lives each year."

Financial and other terms of the agreement were not disclosed.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.